- Home
- ATXS vs CYRX Comparison
ATXS vs CYRX Comparison
Compare ATXS & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- CYRX
- Stock Information
- Founded
- ATXS 2008
- CYRX 1999
- Country
- ATXS United States
- CYRX United States
- Employees
- ATXS N/A
- CYRX N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- ATXS Health Care
- CYRX Health Care
- Exchange
- ATXS Nasdaq
- CYRX Nasdaq
- Market Cap
- ATXS 401.2M
- CYRX 422.6M
- IPO Year
- ATXS 2015
- CYRX N/A
- Fundamental
- Price
- ATXS $6.81
- CYRX $6.22
- Analyst Decision
- ATXS Strong Buy
- CYRX Buy
- Analyst Count
- ATXS 6
- CYRX 7
- Target Price
- ATXS $25.67
- CYRX $13.14
- AVG Volume (30 Days)
- ATXS 244.9K
- CYRX 217.7K
- Earning Date
- ATXS 03-03-2025
- CYRX 03-04-2025
- Dividend Yield
- ATXS N/A
- CYRX N/A
- EPS Growth
- ATXS N/A
- CYRX N/A
- EPS
- ATXS N/A
- CYRX N/A
- Revenue
- ATXS N/A
- CYRX $226,113,000.00
- Revenue This Year
- ATXS N/A
- CYRX N/A
- Revenue Next Year
- ATXS N/A
- CYRX $7.61
- P/E Ratio
- ATXS N/A
- CYRX N/A
- Revenue Growth
- ATXS N/A
- CYRX N/A
- 52 Week Low
- ATXS $6.64
- CYRX $5.32
- 52 Week High
- ATXS $16.90
- CYRX $20.11
- Technical
- Relative Strength Index (RSI)
- ATXS 31.94
- CYRX 31.05
- Support Level
- ATXS $6.77
- CYRX $6.61
- Resistance Level
- ATXS $7.30
- CYRX $7.13
- Average True Range (ATR)
- ATXS 0.30
- CYRX 0.41
- MACD
- ATXS 0.02
- CYRX -0.06
- Stochastic Oscillator
- ATXS 14.66
- CYRX 3.65
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.